Evidence map›Paper›PMID 21069703›Full record

SynthesisThe Cochrane database of systematic reviews2010

Percutaneous lines for delivering intravenous antibiotics in people with cystic fibrosis.

Andrew P Prayle, Matthew N Hurley, Alan R Smyth

Open access · bronzeAbstract readSystematic Review
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Andrew P PrayleDepartment of Child Health, School of Clinical Sciences & Nottingham Respiratory BRU, University of Nottingham, E Floor East Block, Queens Medical Centre, Derby Road, Nottingham, UK, NG7 2UH.
Matthew N Hurley
Alan R Smyth
University of Nottingham · GBQueen's Medical Centre · GB

Funding

Department of Health DRF-2009-02-112Department of Health PB-PG-1207-15025Wellcome Trust
6 · The paper itself

Abstract

backgroundPercutaneous long lines (long intravenous lines) and short intravenous lines (also termed cannulae) are both used to deliver intravenous antibiotics in cystic fibrosis to treat respiratory exacerbations of the disease. The perceived advantage of a long intravenous line is a greater duration of line function, which has to be balanced against a technically more challenging insertion procedure, and the possibility of more discomfort on insertion.

objectivesTo compare long intravenous lines with short intravenous lines in people with cystic fibrosis receiving intravenous antibiotics, in terms of lifespan of the line, ease of insertion, complication rates of the line and patient satisfaction. This will help patients and clinicians choose between devices. SEARCH STRATEGY: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Date of most recent search: 26 August 2010. SELECTION CRITERIA: Randomised studies comparing long intravenous lines lines with short intravenous lines or comparing different types of long intravenous lines. DATA COLLECTION AND ANALYSIS: We identified two studies, one comparing long intravenous lines with short intravenous lines, and one comparing two different types of long intravenous lines. MAIN

resultsTwo studies (67 participants) were included in the review. Based on the published reports, both studies had potential for bias in several domains. There is some evidence that long intravenous lines are superior to short intravenous lines. One study of 20 participants found that the lifespan of a long intravenous line is longer than that of a short intravenous line, and that participants preferred the long intravenous lines to short intravenous lines. A further study of 47 participants found no difference in lifespan, or participant preference when comparing two different long intravenous lines (the Hydrocath and Vygon EC). Neither study was powered to detect differences in serious complications of the devices. AUTHORS'

conclusionsThere is some evidence to support the use of long intravenous lines rather than short intravenous lines, in terms of lifespan of the line and patient satisfaction. There is no evidence to suggest that any one type of long intravenous line is superior, and currently choice of line should be determined by operator and patient preference. There are numerous devices available which are used in cystic fibrosis. Further research is required to identify clinically important differences between these devices.

Indexed as

Catheters, IndwellingAnti-Bacterial AgentsBacterial InfectionsCystic FibrosisHumansInfusions, IntravenousLung DiseasesRandomized Controlled Trials as TopicAnti-Bacterial Agents

Identifiers

PMID21069703
PMCPMC6481502
OpenAlexW1846050136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.